(AGENPARL) – SILVER SPRING mer 12 aprile 2023 This guidance describes the Food and Drug Administration’s (FDA or the Agency) regulatory and enforcement priorities regarding the compounding of certain ibuprofen oral suspension products in outsourcing facilities for administration in hospitals and health systems.
Fonte/Source: http://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-certain-ibuprofen-oral-suspension-products-under-section-503b-federal-food-drug-and